| 2.09 0.1 (5.03%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.46 |
1-year : | 2.87 |
| Resists | First : | 2.1 |
Second : | 2.46 |
| Pivot price | 1.95 |
|||
| Supports | First : | 1.84 |
Second : | 1.67 |
| MAs | MA(5) : | 1.97 |
MA(20) : | 1.92 |
| MA(100) : | 2.25  |
MA(250) : | 2.58 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69 |
D(3) : | 59.7 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 3.83 | Low : | 1.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GERN ] has closed above the upper band by 12.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.12 | 2.12 - 2.13 |
| Low: | 1.94 - 1.95 | 1.95 - 1.96 |
| Close: | 2.07 - 2.09 | 2.09 - 2.1 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Mon, 04 Dec 2023
Geron shares rise after positive trial results of blood disorder candidate (NASDAQ:GERN) - Seeking Alpha
Mon, 04 Dec 2023
Should You Accumulate Geron Corp (GERN) Stock Monday Morning? - InvestorsObserver
Mon, 04 Dec 2023
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Im - Benzinga
Thu, 30 Nov 2023
Where Will Geron Corp (GERN) Stock Go Next After It Has Risen 0.51% in a Week? - InvestorsObserver
Thu, 16 Nov 2023
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fri, 03 Nov 2023
Earnings call: Geron Corporation Eyes $3.5 Billion Opportunity in MDS and MF Treatment Market By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 543 (M) |
| Held by Insiders | 4.9613e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 44,940 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.882e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -29 % |
| Return on Assets (ttm) | 31.7 % |
| Return on Equity (ttm) | -36.6 % |
| Qtrly Rev. Growth | 317000 % |
| Gross Profit (p.s.) | -54.64 |
| Sales Per Share | -106.91 |
| EBITDA (p.s.) | -1.14232e+008 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -162 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -1.2 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 3.17 |
| Dividend | 0 |
| Forward Dividend | 4.448e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|